Imaging of myeloma bone lesions
Administering [18F]-FACBC for PET imaging improves the detection and monitoring of myeloma bone lesions by comparing uptake in bone marrow, addressing the limitations of FDG-PET for myeloma diagnosis.
Patent Information
- Application Number
- JP2024539504
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-07
- Filing Date
- 2023-01-09
- Publication Date
- 2025-01-09
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current PET imaging agents like FDG-PET have low sensitivity and specificity for detecting myeloma bone lesions, necessitating improved methods for reliable and reproducible imaging and diagnosis of myeloma and its recurrence.
Administering the PET contrast agent [18F]-FACBC (anti-1-amino-3-fluorocyclobutane-1-carboxylic acid) and comparing its uptake in bone marrow surrounding potential lesions to enhance diagnostic accuracy through PET imaging.
Enhances the detection and monitoring of myeloma bone lesions by providing more reliable PET imaging, allowing for accurate diagnosis and monitoring of myeloma recurrence.
Smart Images

Figure 2025500574000001 
Figure 2025500574000002 
Figure 2025500574000003
Abstract
Description
[Technical field]
[0001] This disclosure is 18 The present invention relates to a method for administering [F]-FACBC to a subject in a method for imaging and diagnosing bone lesions in myeloma. 18 F]-FACBC. [Background technology]
[0002] [ 18 F]-FACBC, FACBC, or anti-1-amino-3- 18 Fluciclovine, also known as F-fluorocyclobutane-1-carboxylic acid ( 18 F) is a synthetic amino acid imaging agent that is taken up by amino acid transporters and used for positron emission tomography (PET), which is uniquely suited to assess metabolic activity in human tissues for diagnostic imaging purposes. 18 [F]-fluoro-2-deoxy-glucose (FDG) is a PET imaging agent for the detection and localization of many forms of cancer. However, FDG-PET has been found to have low sensitivity and / or specificity for the evaluation of some types of cancer, e.g., myeloma. Summary of the Invention [Problem to be solved by the invention]
[0003] Detection of focal bone lesions by imaging in suspected myeloma directly impacts the patient's final diagnosis and subsequent management. Therefore, there is a need for imaging methods that allow reproducible and reliable imaging for the detection and monitoring of myeloma in bone. [Means for solving the problem]
[0004] The present disclosure provides a method for improved PET imaging and more reliable diagnosis of cancer or its recurrence. 18In particular, the present disclosure relates to a method for diagnosing myeloma bone lesions in a subject by administering [F]-FACBC to a subject for improved PET imaging and more reliable diagnosis of myeloma bone lesions and their recurrence. 18 The present disclosure relates to a method for administering the PET imaging agent [F]-FACBC. 18 The present invention further relates to a method for diagnosing bone lesions and their recurrence in myeloma using [F]-FACBC. 18 In lesions with potential for F]-FACBC uptake, 18 Comparison of uptake, such as [F]-FACBC uptake, may allow for a more accurate diagnosis of the lesion.
[0005] In an embodiment of the disclosure, there is provided a method of diagnosing myeloma bone lesions in a subject, comprising: a) administering to the subject a detectable amount of 18 administering [F]-FACBC; b) obtaining one or more positron emission tomography (PET) scan images of the subject of a site (a site including one or more regions of interest) that contains a bone lesion that may be myeloma; and c) in the bone marrow surrounding the site 18 F]-FACBC uptake in bone lesions with possible myeloma 18 and comparing [F]-FACBC uptake, Lesion 18 F]-FACBC uptake in the surrounding bone marrow 18 F]-FACBC uptake, Steps A method is provided that includes:
[0006] In an embodiment of the present disclosure, 18 F]-FACBC, a) administering to the subject a detectable amount of 18 administering [F]-FACBC; b) obtaining one or more positron emission tomography (PET) scan images of the subject of a region of the subject containing a bone lesion likely to be myeloma; c) in the bone marrow surrounding the site 18 F]-FACBC uptake in bone lesions with possible myeloma 18 comparing [F]-FACBC uptake; and d) determining whether the possible lesion is a myeloma bone lesion based on the analysis of step c). A method is provided that includes:
[0007] In an exemplary method, the lesion 18 F]-FACBC uptake in the bone marrow 18 F]-FACBC activity is visually compared to that of the bone marrow. 18 F]-FACBC uptake is considered suspicious for myeloma. 18 F]-FACBC uptake is considered suspicious for myeloma.
[0008] In another embodiment of the present disclosure, there is provided a kit for imaging, diagnosing, and / or monitoring myeloma, comprising: a) a 18 [F]-FACBC tracer and b) instructions for administration according to the methods disclosed herein.
[0009] In an embodiment of the present disclosure, image acquisition using PET / MRI or PET / CT scanner is provided. Simultaneous or sequential image acquisition in PET / MRI or PET / CT scanner may improve diagnostic accuracy through the generation of images in separate devices. Conjoint use with CT or MRI may improve the localization of lesions, especially small lesions (e.g., largest cross section <1 cm), for example, in the case of small myeloma bone lesions. The method of administration may be as described herein.
[0010] In an embodiment of the present disclosure, 18 A method of using [F]-FACBC comprising the steps of: a) administering to the subject a detectable amount of 18 F]-FACBC; and b) obtaining one or more positron emission tomography (PET) scan images of the subject of a region of the subject that includes a bone lesion that may be myeloma; To determine whether a possible lesion is a bone lesion of myeloma, 18 F]-FACBC uptake in the surrounding bone marrow 18 F]-FACBC uptake. Before the PET scan begins, the subject is positioned in a supine position with arms at their sides, the scan begins at the top of the subject's head and continues to the extremities of the subject, and the scan 18 Beginning 3–5 min after [F]-FACBC administration and continuing for a total scan time of up to 30 min, The subject is: i) 18 No food or calorie-containing beverages, except clear water and medications, should be consumed for at least 4 hours prior to administration of [F]-FACBC; and ii) Avoid significant exercise for at least 1 day prior to the PET scan. He has been instructed in the following: Myeloma-like bone lesions 18 F]-FACBC uptake in the surrounding bone marrow 18 F]-FACBC uptake is indicative of the presence of myeloma. Steps A method is provided that includes:
[0011] In an embodiment of the present disclosure, 18 F]-FACBC, obtaining one or more positron emission tomography (PET) scan images of a region of the subject containing a bone lesion suspected to be myeloma, the one or more PET scan images being acquired while the subject is positioned in a supine position with arms at their sides, the scan beginning at the top of the subject's head and continuing to the extremities of the subject, and the scan including a PET scan of the subject; 18 step, beginning 3–5 min after [F]-FACBC administration and continuing for a total scan time of up to 30 min; In bone lesions that may be myeloma 18 F]-FACBC uptake in the surrounding bone marrow 18 analyzing the one or more PET scan images by comparing [F]-FACBC uptake; and This step determines the state of bone lesions that may be myeloma based on the analysis, and 18 F]-FACBC uptake in the surrounding bone marrow 18 Higher [F]-FACBC uptake suggests the presence of myeloma. A method is provided that includes:
[0012] In an embodiment of the disclosure, an anti-1-amino-3- 18 F-fluorocyclobutane-1-carboxylic acid, which is used in the process of the following steps: a) administering to the subject a detectable amount of 18 administering [F]-FACBC; b) obtaining one or more positron emission tomography (PET) scan images of the subject of a region of the subject containing a bone lesion likely to be myeloma; c) in the bone marrow surrounding the site 18 F]-FACBC uptake in bone lesions with possible myeloma 18 comparing [F]-FACBC uptake; and d) determining whether the possible lesion is a myeloma bone lesion based on the analysis of step c). Anti-1-amino-3- 18 F-Fluorocyclobutane-1-carboxylic acid ([ 18 F]-FACBC) is provided.
[0013] Such methods may further comprise the step of prescribing a treatment regimen for the subject based on the determined status of the possible myeloma bone lesion. The methods disclosed herein may be used for non-diagnostic purposes.
[0014] Any upper and lower limit of the amount, range, and ratio specified herein may be combined independently. Thus, any upper and lower limit of the amount, range, and ratio specified herein in relation to a particular technical feature of the present invention may be combined independently with any upper and lower limit of the amount, range, and ratio specified herein in relation to one or more other particular technical features of the present invention. Furthermore, any particular technical feature of the present invention, and all preferred variants thereof, may be combined independently with any other particular technical feature, and all preferred variants thereof, whether such feature is preferred or not.
[0015] It will also be understood that preferred features of each aspect of the invention are to be considered as preferred features of each and every aspect of the invention. [Brief description of the drawings]
[0016] [Figure 1] [18F]-FACBC PET (left) coronal and PET / CT (right) fusion images of the lumbar spine. The arrow in the right image indicates the area diagnosed as diseased, which has higher [18F]-FACBC uptake than the surrounding bone marrow (indicated by a square). Acquisition of this PET scan began 5 minutes after administration of 319MBq [18F]-FACBC. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] The term "about" refers to being approximately the same as a reference number or value, and should generally be understood to encompass ±5% of the given amount or value. The present inventors have established a protocol that allows for more reliable imaging of bone lesions, for example, by analyzing and comparing data from PET scan images in order to more accurately diagnose and / or monitor myeloma bone lesions and areas suspected of being myeloma bone lesions. 18 In lesions with potential for F]-FACBC uptake, 18 Comparison of uptake, such as [F]-FACBC uptake, may allow for a more accurate diagnosis of the lesion.
[0018] A method for detecting a lesion in a subject (e.g., a patient), comprising administering to the subject 18 Disclosed are methods comprising administering [F]-FACBC and imaging the subject with a PET / MRI or PET / CT scanner to obtain coordinated PET and MRI and / or PET and CT images. The lesion may be a myeloma bone lesion. Methods of administration and / or PET imaging may be as follows:
[0019] In an embodiment of the disclosure, there is provided a method of diagnosing myeloma bone lesions in a subject, comprising: (a) administering to a subject a detectable amount of 18 administering [F]-FACBC; (b) obtaining one or more positron emission tomography (PET) scan images of the subject of a region of the subject that includes a bone lesion that may be myeloma; (c) in the bone marrow of the subject at the site 18 In lesions with potential for F]-FACBC uptake, 18 comparing [F]-FACBC uptake; Bone marrow 18 F]-FACBC uptake in lesions with higher [ 18 F]-FACBC uptake suggests the presence of myeloma bone disease; Steps A method is provided that includes:
[0020] In step a), 18 [F]-FACBC may be injected as an intravenous bolus injection, which may be followed by a saline flush, for example, a saline flush of about 10 mL or less.
[0021] Amino acids are important nutrients for the growth of the lesion. After injection, the lesion cells 18 F]-FACBC, and cells that have taken up the tracer can then be visualized, for example, via PET imaging. Acquisition of PET scan images can begin 3-5 minutes after the end of the injection, for example, 4 minutes after the end of the injection. In some instances, acquisition can begin 3, 4, or 5 minutes after the end of the injection. 18 [F]-FACBC can be taken up by diseased cells relatively quickly compared to other PET radiotracers with different uptake mechanisms. For example, in FDG-PET imaging, acquisition usually begins at least 45 minutes after injection.
[0022] [ 18 A detectable amount of [F]-FACBC is taken up by diseased cells, allowing detection of these cells by PET imaging. 18 In some instances, the dose of [F]-FACBC is 18 The dose of [F]-FACBC is 370±20% MBq, for example, 370 MBq (+ / - 10%) or 370 MBq (+ / - 5%). The dose may be diluted to 10 mL.
[0023] In some embodiments, the subject (e.g., patient) is 18The subject fasts for at least 4 hours, e.g., 4 to 6 hours, prior to administration of [F]-FACBC. For example, the administration instructions may include instructing the subject to 18 F]-FACBC, and / or the health care professional may instruct the subject to fast for at least 4 hours prior to administration of F]-FACBC. 18 Patients may be advised to fast for at least 4 hours prior to administration of [F]-FACBC. The term "fasting" means not consuming food or calorie-containing fluids. For example, only water (e.g., clear water) or other non-calorie-containing fluids or medications (e.g., prescribed medications) may be consumed within the 4 hours prior to administration.
[0024] Additionally or alternatively, the subject may avoid significant exercise for at least one day prior to the PET scan. The PET imaging technique may utilize a scanning device that detects the 511 keV annihilation photons emitted after the radioactive decay of fluorine-18. In addition, "micro-PET" scanners, which have high spatial resolution, may be used for imaging of small animals. In addition to PET scanners, 18 F-radioactivity can further be monitored using one or more radiation detector probes.
[0025] In step b) of the exemplary methods herein, the acquisition / scan time may start 3-5 minutes after the end of the injection, for example 4 minutes after the end of the injection. In some instances, a PET scan begins at the vertex of a subject (the top of the subject's head) and continues to the extremities of the subject (the bottom of the subject's feet), so, for example, the PET scan may include substantially all of a subject's body.
[0026] In another embodiment, there is provided a method of imaging myeloma in a subject, comprising: a) administering to the subject a detectable amount of 18 A first dose of [F]-FACBC is administered to one or more areas of interest within the subject. 18 allowing time for [F]-FACBC to accumulate; b) obtaining a first PET scan image of the subject for one or more regions of interest in the subject that contain a bone lesion suspected to be myeloma; c) administering to the subject a detectable amount of 18 A second dose of [F]-FACBC is administered to the subject in one or more areas of interest. 18 allowing time for [F]-FACBC to accumulate; d) obtaining a second PET scan image of the subject regarding one or more regions of interest; e) For the first and second PET scan images, [ 18 In lesions with potential for F]-FACBC uptake, 18 comparing [F]-FACBC uptake; The first and second scan images are 18 F]-FACBC position and intensity, 18 the location of [F]-FACBC indicates the presence of diseased tissue in the subject; Steps A method is provided that includes:
[0027] In a further embodiment, there is provided a method of diagnosing or monitoring myeloma in a subject, comprising: a) administering to the subject a detectable amount of 18 A first dose of [F]-FACBC is administered to one or more areas of interest in the subject that contain a potential myeloma bone lesion. 18 allowing time for [F]-FACBC to accumulate; b) [ 18 obtaining a first PET scan image of the subject showing the location and intensity of [F]-FACBC; c) administering to the subject a detectable amount of 18 A second dose of [F]-FACBC is administered to the subject in one or more areas of interest. 18 allowing time for [F]-FACBC to accumulate; d) [ 18obtaining a second PET scan image of the subject showing the location and intensity of [F]-FACBC; e) Compare the first and second scans and 18 determining whether the location and / or intensity of [F]-FACBC has increased, remained constant, or decreased; A method is provided that includes:
[0028] In at least one embodiment of the second or third aspect, both PET and magnetic resonance imaging (MRI) or X-ray computed tomography (CT) scan images are acquired in steps b) and d), for example by use of a combined PET-MRI or PET-CT system.
[0029] In at least one embodiment, [ 18 F]-FACBC is administered according to the aspects of the disclosure discussed above. In steps a) and c) of the above embodiment, 18 The time required for [F]-FACBC to accumulate in diseased cells is sufficient. 18 F]-FACBC is administered for about 5 minutes or less. 18 The time required for the accumulation of [F]-FACBC is 3 to 5 minutes, e.g., about 4 minutes. Thus, this means that 3 to 5 minutes after administration, e.g., 18 Allow image acquisition to begin approximately 4 min after [F]-FACBC administration.
[0030] Once data is collected from the first PET scan, the images can be visualized and the lesions in the subject [ 18 F]-FACBC uptake level, volume, and / or location. Images are typically interpreted visually by a nuclear medicine physician or radiologist, and standardized uptake values (SUVs), such as SUVmax and SUVmean, may be measured.
[0031] The period between the acquisition of the first and second PET scan images, i.e., between steps b) and d) of the above embodiment, can be as long as one year. In some examples, the period between the first and second PET scans is about one month to about 12 months, such as 6 months, 5 months, 4 months, 3 months, 2 months, or 1 month, or less than about one month. Steps c) and d) of the above second and third embodiments can be repeated as many times as necessary to obtain multiple scan images that can be used to map the development of the lesion over time.
[0032] When image data was collected from the second PET scan, both the first and second images were visualized and the lesions in the subjects [ 18 F]-FACBC uptake, which may be used to study changes in the extent and location of myeloma, allowing for the diagnosis or monitoring of myeloma. 18 If the level of [F]-FACBC uptake has changed, the subject may be diagnosed with myeloma relapse. In some embodiments, the second scan image, in addition to being compared to the first PET scan, may be compared to an image of data collected from a previous PET scan taken before the first PET scan. Additionally, any subsequent PET scan images obtained after the second PET scan image may be compared to the first and / or second PET scan images.
[0033] By comparing images from two or more different time points, 18 The difference in lesion uptake of [F]-FACBC can be analyzed. Comparison can involve qualitative image comparison (e.g., level of lesion uptake against background) and / or quantitative index obtained from imaging or extracorporeal radiation detection data (e.g., SUV). Thus, the occurrence, progression, or decline of all lesions can be monitored and diagnosed accordingly. Appropriate treatment can then be determined, such as, for example, targeted administration of local treatment at the site of the lesion. It will be understood that the methods described herein can also be used to monitor the response to various treatment regimens.
[0034] The PET scan images obtained in steps b) and d) of the above method may be combined, preceded, or followed by anatomical imaging selected from computed tomography (CT) imaging, computed axial tomography (CAT) imaging, or MRI. For combined imaging, the images may be acquired using dedicated PET-CT, PET-MRI, or separate PET and CT / MRI scanning devices. When separate PET and CT / MRI imaging devices are used, image analysis techniques may be employed to spatially register the PET images with the anatomical images.
[0035] In at least one embodiment, image acquisition steps b) and d) include obtaining combined PET and MRI scan images. PET-MRI images may be obtained using dedicated PET-MRI scanning equipment. Such scanning equipment is available from Siemens (Biograph mMR) and GE (SIGNA PET / MR). As MRI does not use ionizing radiation, its use may be preferred over CT. An advantage of PET-MRI acquisition is that only the patient and medical staff need be present for a single scan, resulting in a more time and cost efficient process.
[0036] In another embodiment, image acquisition steps b) and d) include obtaining combined PET and CT scan images. PET-CT images may be obtained using a dedicated PET-CT scanning device. The advantage of PET-CT acquisition is that only the patient and medical staff need to be present for a single scan, resulting in a more time and cost efficient process.
[0037] It is contemplated that the methods described herein are suitable for detecting myeloma bone lesions. The methods described herein may be suitable for detecting recurrence of myeloma bone lesions.
[0038] In an exemplary embodiment, the methods of the disclosure are used to diagnose recurrence of myeloma bone lesions. The methods herein may include prescribing a treatment regimen, such as, for example, pharmaceuticals and / or surgical procedures, among other treatment options, based on the analysis of the PET scan images. The analysis may include determining whether the bone lesions that may be myeloma are causing the disease. 18 F]-FACBC uptake may indicate the presence of myeloma in the subject.
[0039] The methods of the disclosure may be used in humans, and some methods may be used in non-human animals (eg, dogs and cats). Another aspect of the present disclosure is a kit for imaging, diagnosing, and / or monitoring myeloma, comprising: a) a kit for imaging, diagnosing, and / or monitoring myeloma comprising: 18 F]-FACBC tracer; b) instructions for administration according to the embodiments of the present disclosure discussed above.
[0040] Although the present disclosure has been described above with reference to specific embodiments, it is not intended that the disclosure be limited to the specific forms set forth herein, but rather that the present invention is limited only by the scope of the appended claims, and other embodiments other than those specifically described above are equally possible within the scope of these appended claims.
Claims
1. Anti-1-amino-3-amino-peptide for use in determining whether a possible lesion is a myeloma bone lesion 18 F-fluorocyclobutane-1-carboxylic acid, which is used in the preparation of a compound comprising the steps of: a) administering to a subject a detectable amount of [ 18 F]-FACBC; b) obtaining one or more positron emission tomography (PET) scans of the subject of a region of the subject that includes a bone lesion that may be myeloma; c) in the bone marrow surrounding the site 18 F]-FACBC uptake in bone lesions with possible myeloma 18 F]-FACBC uptake; and d) determining whether the possible lesion is a myeloma bone lesion based on the analysis of step c). Anti-1-amino-3- 18 F-fluorocyclobutane-1-carboxylic acid ([ 18 F]-FACBC).
2. [ 18 F]-FACBC, comprising: a) administering to a subject a detectable amount of [ 18 F]-FACBC; b) obtaining one or more positron emission tomography (PET) scans of the subject of a region of the subject that includes a bone lesion that may be myeloma; c) in the bone marrow surrounding the site 18 F]-FACBC uptake in bone lesions with possible myeloma 18 F]-FACBC uptake; and d) determining whether the possible lesion is a myeloma bone lesion based on the analysis of step c). The method includes:
3. [0043] 18 F]-FACBC uptake in the surrounding bone marrow 18 3. The compound or method of claim 1, wherein the FACBC uptake is higher than F]-FACBC uptake.
4. 4. The compound or method of any one of claims 1 to 3, wherein step c) comprises determining the absence of myeloma bone lesions.
5. Administered to the subject 18 5. The compound or method of any one of claims 1 to 4, wherein the dose of [F]-FACBC is 370MBq (+ / - 20%).
6. Administered to the subject 18 6. The compound or method of any one of claims 1 to 5, wherein the dose of [F]-FACBC is 370MBq (+ / - 10%).
7. Administered to the subject 18 7. The compound or method of any one of claims 1 to 6, wherein the dose of [F]-FACBC is 370MBq (+ / - 5%).
8. Administered to the subject 18 8. The compound or method of any one of claims 1 to 7, wherein the dose of [F]-FACBC is 370 MBq.
9. [ 18 9. The compound or method of any one of claims 1 to 8, wherein [F]-FACBC is injected into the subject as an intravenous bolus.
10. [ 18 10. The compound or method of any one of claims 1 to 9, wherein administration of [F]-FACBC is followed by an intravenous saline flush.
11. 11. A compound or method according to any one of claims 1 to 10, wherein before the PET scan begins the subject is placed in a supine position with arms at their sides.
12. 12. The compound or method of any one of claims 1 to 11, wherein the PET scan begins at the top of the subject's head and continues to the subject's extremities.
13. The PET scan 18 13. The compound or method of any one of claims 1 to 12, wherein the scan begins 3-5 minutes after administration of [F]-FACBC and continues for a total scan time of up to 30 minutes.
14. The PET scan 18 14. The compound or method of any one of claims 1 to 13, wherein the administration of F]-FACBC is initiated 4 minutes after administration of F-FACBC.
15. The object is i) 18 Have not consumed any food or calorie-containing beverages, except clear water and medications, for at least 4 hours prior to administration of [F]-FACBC; and ii) Avoided significant exercise for at least 1 day prior to the PET scan 15. A compound or method according to any one of claims 1 to 14.
16. a) administering to the subject a dose of 370 MBq (+ / - 20%) [ 18 F]-FACBC administered as an intravenous bolus injection followed by an intravenous saline flush; b) obtaining one or more PET scans of the subject; and c) Myeloma-like bone lesions 18 F]-FACBC uptake in the surrounding bone marrow 18 F]-FACBC uptake, Before the PET scan begins, the subject is placed in a supine position with arms at their sides, the scan begins at the top of the subject's head and continues to the extremities of the subject, and the scan 18 F]-FACBC administration starting 3-5 min and continuing for a maximum total scan time of 30 min; The object is i) 18 Have not consumed any food or calorie-containing beverages, except clear water and medications, for at least 4 hours prior to administration of [F]-FACBC; and ii) have avoided significant exercise for at least 1 day prior to the PET scan; and Myeloma-like bone lesions 18 F]-FACBC uptake in the surrounding bone marrow 18 F]-FACBC uptake indicates the presence of myeloma.
16. The compound or method of any one of claims 1 to 15, comprising:
17. 17. The compound or method of any one of claims 1 to 16, wherein a PET and magnetic resonance imaging (MRI) scan image or a PET and X-ray computed tomography (CT) scan image is obtained in step b).
18. the one or more PET scan images are a first one or more PET scan images, and the method further comprises: e) repeating steps a) through d) after a period of time and comparing the subsequent PET scan or scans with the first PET scan or scans to determine whether the bone lesions are due to possible myeloma. 18 Determining whether F]-FACBC uptake increases, remains constant, or decreases.
18. The compound or method of any one of claims 1 to 17, further comprising:
19. 19. The compound or method of any one of claims 1 to 18, wherein the period of time is at least 6 months.
20. [ 18 F]-FACBC comprising the steps of: a) administering to a subject a detectable amount of [ 18 F]-FACBC; and b) obtaining one or more positron emission tomography (PET) scans of the subject for a region of the subject that includes a bone lesion that may be myeloma; To determine whether a possible lesion is a bone lesion of myeloma, the following criteria were used: 18 F]-FACBC uptake was associated with [ 18 F]-FACBC uptake, Before the PET scan begins, the subject is placed in a supine position with arms at their sides, the scan begins at the top of the subject's head and continues to the extremities of the subject, and the scan 18 F]-FACBC administration starting 3-5 min and continuing for a maximum total scan time of 30 min; The subject is i) 18 Abstain from food or calorie-containing beverages, except for clear water and medications, for at least 4 hours prior to administration of [F]-FACBC; and ii) have been instructed to avoid significant exercise for at least one day prior to the PET scan; Myeloma-like bone lesions 18 F]-FACBC uptake in the surrounding bone marrow 18 F]-FACBC uptake indicates the presence of myeloma. Steps The method includes:
21. [ 18 F]-FACBC, comprising: obtaining one or more positron emission tomography (PET) scan images of a region of the subject containing a possible myeloma bone lesion, the one or more PET scan images being acquired while the subject is positioned in a supine position with arms at their sides, the scan beginning at the top of the subject's head and continuing to the extremities of the subject, and the scan including a PET scan of the subject's bone mass; 18 F]-FACBC administration starting 3-5 minutes after administration and continuing for a total scan time of up to 30 minutes; Myeloma-like bone lesions 18 F]-FACBC uptake in the surrounding bone marrow 18 F]-FACBC uptake. determining the status of the bone lesions that may be myeloma based on the analysis, 18 F]-FACBC uptake in the surrounding bone marrow 18 F]-FACBC uptake indicates the presence of myeloma. The method includes:
22. 22. The method of claim 21, further comprising the step of prescribing a treatment regimen for the subject based on the determined status of the likely myeloma bone lesion.
